scispace - formally typeset
D

Daniel J. Drucker

Researcher at Lunenfeld-Tanenbaum Research Institute

Publications -  430
Citations -  65500

Daniel J. Drucker is an academic researcher from Lunenfeld-Tanenbaum Research Institute. The author has contributed to research in topics: Glucagon & Glucagon-like peptide-1. The author has an hindex of 123, co-authored 412 publications receiving 58470 citations. Previous affiliations of Daniel J. Drucker include University of North Carolina at Chapel Hill & Mount Sinai Hospital.

Papers
More filters
Journal ArticleDOI

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

TL;DR: Clinical trials with the incretin mimetic exenatide and liraglutide show reductions in fasting and postprandial glucose concentrations, and haemoglobin A1c (HbA1c) associated with weight loss, but long-term clinical studies are needed to determine the benefits of targeting the inc retin axis for the treatment of type 2 diabetes.
Journal ArticleDOI

Biology of Incretins: GLP-1 and GIP

TL;DR: This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).
Journal ArticleDOI

The biology of incretin hormones.

TL;DR: Current concepts of incretin action are summarized and the potential therapeutic utility of GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes is highlighted.
Journal ArticleDOI

Normalization of obesity-associated insulin resistance through immunotherapy.

TL;DR: It is discovered that CD4+ T lymphocytes, resident in visceral adipose tissue (VAT), control insulin resistance in mice with diet-induced obesity (DIO), andalyses of human tissue suggest that a similar process may also occur in humans.